Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Jiliang Qiu"'
Autor:
Yichuan Yuan, Hong Peng, Wei He, Yun Zheng, Jiliang Qiu, Bin Chen, Ruhai Zou, Chenwei Wang, Wan Yee Lau, Binkui Li, Yunfei Yuan
Publikováno v:
Cancer Communications, Vol 44, Iss 11, Pp 1337-1349 (2024)
Abstract Background The widely accepted view that portal hypertension (PHT) is a contraindication to hepatectomy for patients with hepatocellular carcinoma (HCC) is being increasingly challenged. The long‐term survival outcomes and safety of partia
Externí odkaz:
https://doaj.org/article/6c1ec63e0dd24406aebdde4ad6087bfa
Autor:
Yunxing Shi, Zongfeng Wu, Shaoru Liu, Dinglan Zuo, Yi Niu, Yuxiong Qiu, Liang Qiao, Wei He, Jiliang Qiu, Yunfei Yuan, Guocan Wang, Binkui Li
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract Immune checkpoint blockade (ICB) has emerged as a promising therapeutic option for hepatocellular carcinoma (HCC), but resistance to ICB occurs and patient responses vary. Here, we uncover protein arginine methyltransferase 3 (PRMT3) as a dr
Externí odkaz:
https://doaj.org/article/fad2f9efb58746b78126f9a34579a7ff
Autor:
Zhu Lin, Zhenkun Huang, Jiliang Qiu, Yunxing Shi, Dinglan Zuo, Zhiyu Qiu, Wei He, Yi Niu, Yunfei Yuan, Binkui Li
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-18 (2024)
Abstract Background The escalating prevalence of metabolic diseases has led to a rapid increase in non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (NASH-HCC). While oxaliplatin (OXA)-based hepatic arterial infusion chemotherapy
Externí odkaz:
https://doaj.org/article/964523ec79474b6f96431b8f37d1cace
Autor:
Yunxing Shi, Kai Li, Yichuan Yuan, Chenwei Wang, Zhiwen Yang, Dinglan Zuo, Yi Niu, Jiliang Qiu, Binkui Li, Yunfei Yuan, Wei He
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract N6-methyladenosine (m6A) is important in regulating mRNA stability, splicing, and translation, and it also contributes to tumor development. However, there is still limited understanding of the comprehensive effects of m6A modification patte
Externí odkaz:
https://doaj.org/article/ffb6b073927d4e0fa45b3c486bc3d278
Autor:
Yanhong Lang, Chengrui Zhong, Lingling Guo, Zhijie Liu, Dinglan Zuo, Xi Chen, Liuyan Ding, Bijun Huang, Binkui Li, Yunfei Yuan, Yi Niu, Jiliang Qiu, Chaonan Qian
Publikováno v:
iScience, Vol 27, Iss 7, Pp 110205- (2024)
Summary: Monoacylglycerol acyltransferase-2 (MOGAT2), encodes MOGAT enzyme in the re-synthesis of triacylglycerol and protects from metabolism disorders. While, its precise involvement in colorectal cancer (CRC) progression remains inadequately under
Externí odkaz:
https://doaj.org/article/0b8a8900b2454e0fbbbda23fcefc1356
Autor:
Liang Qiao, Wei He, Guoying Wang, Huanwei Chen, Fuxi Huang, Bo Zhang, Yuxiong Qiu, Shaoru Liu, Zhenkun Huang, Yichuan Yuan, Jiliang Qiu, Yunfei Yuan, Binkui Li
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Introduction Regorafenib remains the standard and widely used second‐line strategy for advanced hepatocellular carcinoma (HCC). There is still a lack of large‐scale multicenter real‐world evidence concerning the concurrent use of regor
Externí odkaz:
https://doaj.org/article/d7b100f5750b4f9486922d99dd9bd705
Autor:
Shilei Bai, Pinghua Yang, Jiliang Qiu, Jie Wang, Liu Liu, Chunyan Wang, Huifeng Wang, Zhijian Wen, Baohua Zhang
Publikováno v:
Cancer Reports, Vol 7, Iss 3, Pp n/a-n/a (2024)
Abstract Background Surgical resection remains the primary treatment option for gallbladder carcinoma (GBC). However, there is a pressing demand for prognostic tools that can refine patients' treatment choices and tailor personalized therapies accord
Externí odkaz:
https://doaj.org/article/e9d9b46b561849d2b49c74840f623e02
Autor:
Fangfang Bi, Yuxiong Qiu, Zongfeng Wu, Shaoru Liu, Dinglan Zuo, Zhenkun Huang, Binkui Li, Yunfei Yuan, Yi Niu, Jiliang Qiu
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-11 (2023)
Abstract Methytransferase-like proteins 9 (METTL9) has been characterized as an oncogene in several cancers, however, its role in hepatocellular carcinoma (HCC) remains unknown. Here, we investigated the function and molecular mechanism of METTL9 in
Externí odkaz:
https://doaj.org/article/bd565064afc44b64ba5f9c36097170c6
Autor:
Zhiyu Qiu, Chenwei Wang, Pinzhu Huang, Yichuan Yuan, Yunxing Shi, Zhu Lin, Zhenkun Huang, Dinglan Zuo, Jiliang Qiu, Wei He, Jingxian Shen, Yi Niu, Yunfei Yuan, Binkui Li
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 12, Pp n/a-n/a (2023)
Abstract Background Hepatocellular carcinoma (HCC) cells undergo reprogramming of glucose metabolism to support uncontrolled proliferation, of which the intrinsic mechanism still merits further investigation. Although regulatory factor X6 (RFX6) is a
Externí odkaz:
https://doaj.org/article/2b5da3cad401449583a5aef63c4d40d1
Autor:
Yunxing Shi, Yi Niu, Yichuan Yuan, Kai Li, Chengrui Zhong, Zhiyu Qiu, Keren Li, Zhu Lin, Zhiwen Yang, Dinglan Zuo, Jiliang Qiu, Wei He, Chenwei Wang, Yadi Liao, Guocan Wang, Yunfei Yuan, Binkui Li
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Despite being an effective treatment for hepatocellular carcinoma (HCC), resistance to oxaliplatin presents a major obstacle. Here, the authors identify PRMT3-induced methylation of IGF2BP1 resulting in HEG1 stabilisation as a mechanism of oxaliplati
Externí odkaz:
https://doaj.org/article/e53d3f37541e43b8bb367b490a8105d2